# Can IGF-1 LR3 modulate inflammation in aging-related colitis?

Canonical source: https://retacompare.com/research/can-igf-1-lr3-modulate-inflammation-in-aging-related-colitis

Peptide Longevity Q&A · 2021-01-28


    Research indicates that IGF-1 LR3 may play a role in modulating inflammation, as shown by the decreased serum IGF-1 levels in mice treated with MIA-690 in a model of DSS-induced colitis. This suggests a potential protective effect against chronic inflammatory conditions.

 What the research shows

The study investigated the effects of growth hormone-releasing hormone (GHRH) analogs, specifically MIA-690 and MR-409, on inflammation in a mouse model of dextran sodium sulfate (DSS)-induced colitis. The researchers measured the production of pro-inflammatory markers and oxidative stress indicators in colon specimens from mice subjected to inflammatory stimuli. The findings demonstrated that both MIA-690 and MR-409 could decrease the responsiveness to nociceptive stimuli and reduce inflammation-related symptoms in the DSS-induced colitis model.

 Why it matters for longevity

Chronic inflammation is a significant contributor to various age-related diseases, including gastrointestinal disorders. By demonstrating that MIA-690 and MR-409 can attenuate inflammatory responses and lower serum IGF-1 levels, the research suggests that these peptides may have implications for managing inflammation in aging populations. Reducing inflammation could potentially enhance healthspan and mitigate the risks associated with chronic inflammatory diseases.

 Key findings at a glance

MIA-690 and MR-409 reduced pro-inflammatory and oxidative markers in colon specimens.

Both peptides decreased sensitivity to acute and persistent inflammatory stimuli in mice.

MIA-690 showed higher efficacy in inhibiting levels of inflammatory mediators compared to MR-409.

Serum IGF-1 levels were significantly decreased in DSS-treated mice receiving MIA-690.

The study highlights the protective effects of GHRH analogs against inflammation.

 How IGF-1 LR3 works (background)

IGF-1 LR3, a derivative of insulin-like growth factor 1, is known for its role in growth and development, as well as its involvement in metabolic processes. In the context of inflammation, IGF-1 has been shown to influence various signaling pathways that regulate cellular responses to injury and stress. The modulation of IGF-1 levels, as noted in the study, may impact inflammatory responses, potentially contributing to the protective effects observed in the DSS-induced colitis model.

 Safety, caveats, and what we don't yet know

While the findings are promising, the research is limited to preclinical models. Further studies are necessary to understand the long-term effects and safety of GHRH analogs like MIA-690 and MR-409 in humans. Additionally, the specific populations that may benefit from these peptides, particularly in the context of aging and chronic inflammation, have yet to be thoroughly explored.

 Bottom line

Research indicates that IGF-1 LR3 may influence inflammation, particularly through the modulation of serum IGF-1 levels in chronic inflammatory conditions, suggesting potential benefits for managing inflammation in aging.

 Related questions

 Does IGF-1 LR3 play a role in muscle preservation during aging?

Research suggests that IGF-1 LR3 may help mitigate age-related muscle loss by promoting muscle repair and growth, although specific studies directly linking IGF-1 LR3 to sarcopenia are still needed.

 How does IGF-1 LR3 impact metabolic health in older adults?

IGF-1 LR3 is known to influence metabolic processes, potentially aiding in the regulation of glucose metabolism and fat distribution, which are critical for metabolic health in older populations.

 Can IGF-1 LR3 improve recovery from injuries in older individuals?

Preclinical evidence suggests that IGF-1 LR3 may enhance recovery from injuries by promoting tissue repair and reducing inflammation, but further research is required to confirm these effects in older adults.

 Source: PubMed · Sci Rep · published 2021-01-28.

## Sources

- PubMed · Sci Rep: https://pubmed.ncbi.nlm.nih.gov/33510215/